TDMS Study 05109-14 Pathology Tables
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
Facility: Battelle Columbus Laboratory
Chemical CAS #: 102-71-6
Lock Date: 05/31/01
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 7 6 4 7
Moribund Sacrifice 8 10 5 10
Accidently Killed 1
Survivors
Terminal Sacrifice 34 34 41 32
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (50) (50) (50)
Leiomyoma 1 (2%)
Intestine Large, Rectum (50) (50) (50) (50)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Intestine Large, Cecum (50) (50) (50) (50)
Intestine Small, Jejunum (50) (50) (50) (50)
Carcinoma 1 (2%)
Polyp Adenomatous 1 (2%)
Liver (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 5 (10%) 8 (16%) 4 (8%) 5 (10%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 9 (18%) 15 (30%) 13 (26%) 16 (32%)
Hepatocellular Adenoma, Multiple 3 (6%) 7 (14%) 17 (34%)
Histiocytic Sarcoma 4 (8%) 5 (10%) 3 (6%)
Mesentery (11) (6) (4) (9)
Liposarcoma 1 (25%)
Oral Mucosa (26) (26) (31) (31)
Histiocytic Sarcoma 1 (4%)
Pancreas (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Carcinoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Papilloma 2 (4%) 2 (4%) 4 (8%)
Squamous Cell Papilloma, Multiple 1 (2%)
Page 2
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Subcapsular, Adenoma 1 (2%)
Adrenal Medulla (49) (50) (50) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Pituitary Gland (50) (50) (50) (50)
Pars Distalis, Adenoma 8 (16%) 5 (10%) 5 (10%) 5 (10%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 3 (6%) 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicle, Adenoma 1 (2%) 3 (6%)
Follicle, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (50) (50) (50)
Cystadenoma 1 (2%) 1 (2%) 1 (2%)
Granulosa Cell Tumor Malignant 1 (2%)
Histiocytic Sarcoma 2 (4%) 2 (4%) 1 (2%)
Luteoma 1 (2%) 1 (2%)
Teratoma Benign 1 (2%)
Tubulostromal Adenoma 1 (2%)
Page 3
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Uterus (50) (50) (50) (50)
Histiocytic Sarcoma 3 (6%) 3 (6%) 1 (2%)
Leiomyosarcoma 1 (2%) 2 (4%)
Polyp Stromal 1 (2%) 3 (6%) 1 (2%)
Vagina (1)
Leiomyosarcoma, Metastatic, Uterus 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymph Node (6) (7) (4) (6)
Iliac, Histiocytic Sarcoma 1 (14%)
Lumbar, Histiocytic Sarcoma 1 (17%)
Mediastinal, Liposarcoma, Metastatic,
Mesentery 1 (25%)
Renal, Histiocytic Sarcoma 1 (14%)
Lymph Node, Mandibular (49) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (50) (49) (48) (48)
Histiocytic Sarcoma 3 (6%)
Spleen (50) (50) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 3 (6%)
Thymus (49) (49) (49) (49)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Multiple 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Melanoma Malignant,
Multiple 1 (2%)
Subcutaneous Tissue, Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (2) (1) (3)
Hemangiosarcoma, Metastatic, Spleen 1 (100%)
Rhabdomyosarcoma 1 (100%) 2 (100%) 2 (67%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 3 (6%) 2 (4%)
Histiocytic Sarcoma 4 (8%) 4 (8%) 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Osteosarcoma, Metastatic, Skin 1 (2%)
Nose (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (49) (50) (50) (50)
Harderian Gland (49) (50) (50) (50)
Adenoma 5 (10%) 5 (10%) 3 (6%) 3 (6%)
Carcinoma 2 (4%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 2 (4%) 3 (6%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (50) (49) (49)
Page 5
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 4 (8%) 5 (10%) 3 (6%)
Lymphoma Malignant 8 (16%) 9 (18%) 6 (12%) 8 (16%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 41 35 44
Total Primary Neoplasms 63 67 58 84
Total Animals with Benign Neoplasms 24 28 27 38
Total Benign Neoplasms 33 35 41 57
Total Animals with Malignant Neoplasms 27 26 16 21
Total Malignant Neoplasms 30 32 17 27
Total Animals with Metastatic Neoplasms 6 4 2 3
Total Metastatic Neoplasm 6 4 3 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 2 6 8
Natural Death 8 5 10 2
Survivors
Terminal Sacrifice 37 43 34 40
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (50) (50) (50) (50)
Adenoma 1 (2%)
Carcinoma 2 (4%) 1 (2%) 1 (2%)
Carcinoma, Multiple 1 (2%)
Sarcoma, Metastatic, Adrenal Medulla 1 (2%)
Liver (50) (50) (50) (50)
Hemangioma 1 (2%) 2 (4%)
Hemangiosarcoma 1 (2%) 4 (8%) 1 (2%)
Hemangiosarcoma, Multiple 2 (4%)
Hemangiosarcoma, Metastatic, Blood Vessel 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%) 1 (2%) 2 (4%) 3 (6%)
Hepatocellular Carcinoma 11 (22%) 10 (20%) 13 (26%) 10 (20%)
Hepatocellular Carcinoma, Multiple 6 (12%) 4 (8%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 13 (26%) 14 (28%) 12 (24%) 15 (30%)
Hepatocellular Adenoma, Multiple 6 (12%) 4 (8%) 11 (22%) 5 (10%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Sarcoma, Metastatic, Adrenal Medulla 1 (2%)
Mesentery (3) (3) (5) (7)
Fibrous Histiocytoma 1 (14%)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%) 2 (4%) 1 (2%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
Tooth (19) (18) (14) (13)
Odontoma 1 (5%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (50) (50) (50)
Aorta, Hemangiosarcoma 1 (2%)
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Subcapsular, Adenoma 3 (6%) 3 (6%) 6 (12%) 5 (10%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Pituitary Gland (50) (49) (49) (50)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (50) (49) (50)
Follicle, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (1) (1) (1)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (100%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (100%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (100%)
Pancreatic, Fibrous Histiocytoma, Metastatic,
Mesentery 1 (100%)
Renal, Fibrous Histiocytoma 1 (100%)
Lymph Node, Mesenteric (50) (48) (48) (50)
Histiocytic Sarcoma 1 (2%)
Spleen (49) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%) 2 (4%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (48) (47) (48) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Hibernoma 1 (2%)
Subcutaneous Tissue, Melanoma Malignant 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Site of Application -
Dermis, Mast Cell Tumor Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 6 (12%) 11 (22%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 6 (12%) 8 (16%) 3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 8 (16%) 6 (12%) 6 (12%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (49) (50)
Adenoma 6 (12%) 2 (4%) 2 (4%) 5 (10%)
Carcinoma 1 (2%) 1 (2%)
Bilateral, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%) 1 (2%)
Page 11
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Renal Tubule, Carcinoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 01/14/03
Route: SKIN APPLICATION Time: 14:27:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 35 43 41
Total Primary Neoplasms 75 62 80 79
Total Animals with Benign Neoplasms 30 25 32 32
Total Benign Neoplasms 42 35 46 48
Total Animals with Malignant Neoplasms 28 24 27 21
Total Malignant Neoplasms 33 27 34 31
Total Animals with Metastatic Neoplasms 10 8 9 6
Total Metastatic Neoplasm 11 10 12 14
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------